Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors

Journal of Patient-Reported Outcomes

Table 3 Sensitivity and specificity of the PRO-CTCAE items to probable sensory peripheral neuropathy and painful chemotherapy-induced peripheral neuropathy (CIPN)

	Probable sensory peripheral neuropathy + (n = 72)	Probable sensory peripheral neuropathy − (n = 46)
Test + PRO-CTCAE Severity > 0/4	69	16
Test − PRO-CTCAE Severity = 0/4	3	30
	Sensitivity = 95.83%	Specificity = 65.22%
Test + PRO-CTCAE Interference > 0/4	37	12
Test − PRO-CTCAE Interference = 0/4	35	34
	Sensitivity = 51.39%	Specificity = 73.91%

Table describes the sensitivity and specificity of the PRO-CTCAE Numbness and Tingling Severity and Interference Items to probable sensory peripheral neuropathy (n = 118) or painful CIPN (n = 138) at T3. Participants who reported Total Neuropathy Score-Clinical Version (TNSc©) Sensory scores ≥ 1/4 and either TNSc© Sensory Function: Vibration Sensibility scores ≥ 1/4 or TNSc© Reflexes scores ≥ 1/4 were classified as exhibiting probable sensory peripheral neuropathy [38]. Participants who reported TNSc© Sensory scores = 0/4 were classified as not exhibiting probable sensory peripheral neuropathy. Participants who reported 0–10 numerical rating scale of worst CIPN pain intensity scores ≥ 4/10 over the past week were interpreted as indicating the presence of painful CIPN [39]. Participants who reported < 4/10 worst CIPN pain intensity over the past week were classified as not experiencing painful CIPN. Higher scores on all measures represented worse symptom severity